

## donanemab (Kisunla®)

SMC Drug ID	Conditions	Decision	Date published on SMC Website	Date of decision / Expected date of decision
SMC2687	for the treatment of mild cognitive impairment and mild dementia due to Alzheimer's disease (AD) in adult patients that are apolipoprotein E ε4 (ApoE ε4) heterozygotes or non-carriers.	Not routinely available as not recommended for use in NHS Scotland	12/05/2025	23/04/2025
<b>Other Decision Specified :</b>				
<b>Web Link :</b> <a href="https://scottishmedicines.org.uk/media/9140/donanemab-kisunla-final-april-2025-for-website.pdf">https://scottishmedicines.org.uk/media/9140/donanemab-kisunla-final-april-2025-for-website.pdf</a>				

## sodium thiosulfate (Pedmarqsi®)

SMC Drug ID	Conditions	Decision	Date published on SMC Website	Date of decision / Expected date of decision
SMC2730	for the prevention of ototoxicity induced by cisplatin chemotherapy in patients 1 month to <18 years of age with localised, non-metastatic, solid tumours.	Routinely available from a specialist centre in another health board	12/05/2025	17/09/2025
<b>Other Decision Specified :</b>				
<b>Web Link :</b> <a href="https://scottishmedicines.org.uk/media/9137/sodium-thiosulfate-pedmarqsi-final-april-2025-for-website.pdf">https://scottishmedicines.org.uk/media/9137/sodium-thiosulfate-pedmarqsi-final-april-2025-for-website.pdf</a>				

<b>erdafitinib (Balversa®)</b>				
<b>SMC Drug ID</b>	<b>Conditions</b>	<b>Decision</b>	<b>Date published on SMC Website</b>	<b>Date of decision / Expected date of decision</b>
SMC2738	as monotherapy for the treatment of adult patients with unresectable or metastatic urothelial carcinoma (UC), harbouring susceptible FGFR3 genetic alterations who have previously received at least one line of therapy containing a PD-1 or PD-L1 inhibitor in the unresectable or metastatic treatment setting.	Available in line with local or regional guidance	12/05/2025	17/09/2025
<b>Other Decision Specified :</b>				
<b>Web Link :</b> <a href="https://scottishmedicines.org.uk/media/9142/erdafitinib-balversa-final-april-2025-for-website.pdf">https://scottishmedicines.org.uk/media/9142/erdafitinib-balversa-final-april-2025-for-website.pdf</a>				
<b>fruquintinib (Fruzaqla®)</b>				
<b>SMC Drug ID</b>	<b>Conditions</b>	<b>Decision</b>	<b>Date published on SMC Website</b>	<b>Date of decision / Expected date of decision</b>
SMC2748	treatment of adult patients with metastatic colorectal cancer (mCRC) who have been previously treated with available therapies, including fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, with or without an anti-VEGF therapy, and if RAS wildtype and medically appropriate, an anti-EGFR therapy.	Not routinely available as not recommended for use in NHS Scotland	12/05/2025	10/08/2025
<b>Other Decision Specified :</b>				
<b>Web Link :</b> <a href="https://scottishmedicines.org.uk/media/9143/fruquintinib-fruzaqla-final-april-2025-for-website.pdf">https://scottishmedicines.org.uk/media/9143/fruquintinib-fruzaqla-final-april-2025-for-website.pdf</a>				

<b>mepolizumab (Nucala®)</b>				
<b>SMC Drug ID</b>	<b>Conditions</b>	<b>Decision</b>	<b>Date published on SMC Website</b>	<b>Date of decision / Expected date of decision</b>
SMC2765	<p>as an add-on treatment for severe refractory eosinophilic asthma in adults, adolescents and children aged 6 years and older.</p> <p>SMC restriction: patients who have eosinophils of at least 150 cells per microlitre (0.15 x 10<sup>9</sup>/L) at initiation of treatment and have had at least three asthma exacerbations in the preceding year or are receiving maintenance treatment with oral corticosteroids.</p>	Not routinely available as the ADTC is waiting for further advice from local clinical experts	12/05/2025	30/03/2026
<b>Other Decision Specified :</b>				
<b>Web Link :</b> <a href="https://scottishmedicines.org.uk/media/9135/mepolizumab-nucala-abb-final-april-2025-for-website.pdf">https://scottishmedicines.org.uk/media/9135/mepolizumab-nucala-abb-final-april-2025-for-website.pdf</a>				
<b>elvitegravir / cobicistat / emtricitabine / tenofovir alafenamide (Genvoya®)</b>				
<b>SMC Drug ID</b>	<b>Conditions</b>	<b>Decision</b>	<b>Date published on SMC Website</b>	<b>Date of decision / Expected date of decision</b>
SMC2809	treatment of human immunodeficiency virus-1 (HIV-1) infection without any known mutations associated with resistance to the integrase inhibitor class, emtricitabine or tenofovir in paediatric patients aged from 2 years and with body weight at least 14 kg to less than 25 kg.	Not routinely available as not recommended for use in NHS Scotland	12/05/2025	23/04/2025
<b>Other Decision Specified :</b> Non-submission				
<b>Web Link :</b> <a href="https://scottishmedicines.org.uk/media/9141/elvitegravir-cobicistat-emtricitabine-tenofovir-alafenamide-genvoya-non-sub-final-april-2025-for-website.pdf">https://scottishmedicines.org.uk/media/9141/elvitegravir-cobicistat-emtricitabine-tenofovir-alafenamide-genvoya-non-sub-final-april-2025-for-website.pdf</a>				

sarilumab (Kevzara®)				
SMC Drug ID	Conditions	Decision	Date published on SMC Website	Date of decision / Expected date of decision
SMC2810	treatment of polymyalgia rheumatica (PMR) in adult patients who have had an inadequate response to corticosteroids or who experience a relapse during corticosteroid taper.	Not routinely available as not recommended for use in NHS Scotland	12/05/2025	23/04/2025
<b>Other Decision Specified :</b> Non-submission				
<b>Web Link :</b> <a href="https://scottishmedicines.org.uk/media/9136/sarilumab-kevzara-non-sub-final-april-2025-for-website.pdf">https://scottishmedicines.org.uk/media/9136/sarilumab-kevzara-non-sub-final-april-2025-for-website.pdf</a>				